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Abstract
Overview: Inflammatory Breast Cancer (IBC) is a rare and very aggressive type of cancer that
tends to develop at a younger age, compared with other subtypes of breast cancer. Because a
distinct lump may not be noticeable, correct diagnosis takes longer and, therefore, successful
treatment may hinder a patient’s prognostics. This study aims to conduct a systematic review of
research articles on IBC. Methods: This is a systematic review of studies in the PubMed database to
April 2013, which fit the eligibility criterion of “Inflammatory Breast Neoplasms” (MeSH Terms),
filtered by Languages (English OR Portuguese OR Spanish). Findings: Of the 119studies identified,
25 complied with the eligibility criterion for the disease, diagnostics, treatment and prognostics.
Conclusion: Despite methodological differences, findings evidence that although IBC presents
particular features (lower survival rate and worse prognostics than most types of breast cancer),
very few studies examine its epidemiology and specific risk factors in depth and use any other
therapeutic approaches than those commonly used for other breast cancer subtypes. Therefore,
further investigation of the disease’s aggressiveness is still necessary.
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INTRODUCTION
Breast cancer is a public health problem, its
incidence increases worldwide. While clinical care
focuses on the individual health, the public health
policies aimed at breast cancer focus the attention
on women from various countries. The goal of these
policies is to establish collective guidelines to
increase health and quality of life through
prevention, treatment of disease and health
behavior promotion1.
Breast cancer brings number of impacts for
women. The challenges and changes resulting from
this disease involve many feelings, implying in
physical and psychical adaptations2.
Inflammatory Breast Cancer (IBC) is a rare,
although highly aggressive and lethal3 type of cancer.
Rapid blood and lymphatic spread and breast tumor
emboli are the main features ofIBC4. With an average
survival rate of three years, IBC accounts for about
2.5% of all breast cancer types in the US. IBC tends
to develop at a younger age than the more common
form of breast cancer5. Distinct signs and symptoms
develop quickly and include redness, thickening
(edema/swelling) and ridging or orange-peel like
textureof the skin – peaud’orange4 in French.
African-American women appear to be at
higher risk of IBC than white women5,6.
The fact that it is a rare form of breast cancer
and rarely causes a breast lump, it is harder to
diagnose at early stage. Thus, successful prognosis
(outlook) and treatment are harder. IBC may be
diagnosed by an imaging test and by a breast biopsy
of an invasive cancer7.
In the past two decades, a multi-therapy
approach has increased the rates of clinical
response through neoadjuvant chemotherapy,
particularly usinganthracyclinesand taxanes-based
combination, surgery, radiotherapy and hormone-
based therapy5.
This study is a systematic review of scientific
articles on IBC with reference to the diagnosis,
treatment, determinants and prognostics of this
type of cancer.
METHODS
Given that a systematic literature review is
directed by a well-formulated question6, this study
attempts to collate all empirical evidence to answer
the following: “What has been researched about
inflammatory breast neoplasms?”
A systematic search was conducted on the
PubMed MEDLINE database, from its inception to
April 2013, originally using the field “MeSH Terms”
and Boolean operators (AND; OR) in “PubMed
Advanced Search Builder” tool with the following
search terms and field:
# 1 “Inflammatory Breast Neoplasms” (MeSH
term);
.
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# 2 Languages (English OR Portuguese OR
Spanish [field]);
The following search was performed: #1 AND
#2.
Articles were assessed as per their
compliance with previously set eligibility criteria,
as follows: a) manuscripts written in English,
Portuguese or Spanish; b) articles about
inflammatory breast neoplasms; c) original articles
with online accessible full text; d) prospective or
retrospective observational (analytical or
descriptive, except case reports), experimental or
quasi-experimental studies. Exclusion criteria were:
a) other designs, such as case reports, series of
cases, review of literature and commentaries; b)
non-original studies, including editorials, reviews,
prefaces, brief communications and letters to the
editor.
Subsequently, every sample was thoroughly
examined and data were entered into a matrix for
multivariate analysis of author, publication year,
description of the study sample and main findings.
Studies that dealt with types other than
inflammatory breast neoplasms, the focus of this
study, were discarded. For each sample, data were
extracted independently if co-authored and
discrepancies were resolved by consensus. Finally,
for heuristic reasons, articles were grouped for
discussion in four major themes: profile
epidemiology, treatment, factor of prognosis and
survival.
RESULTS
The search strategies initially led to 119
references. After browsing the title and abstract of
the retrieved articles for eligibility compliance with
inclusion criteria, 94 articles were discarded and
25 articles were further retrieved and included in
the final sample (Figure 1).
Figure 1. Flow chart showing sample selected for review
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Table 1 provides an overview of the
sample selection process which resulted in the
25 studies of the final sample. Such studies
were grouped into the three previously set
themes: d iagnos is  and t reatment featu-
res4,10,12-19,21,23,26,28  (14  s tud ies) ,  determi -
nants 5,20,25  ( th ree  s tud ies)  and  prognos-
tics3,8,9,11,22,24,27,29 (eight studies).
Table 1: Inflammatory breast neoplasm: studies and main findings
Journal
BMC Cancer
Journal of
Translational
Medicine
Anticancer
Research
Cancer
Cancer
AJR Women 's
Imaging
Annals of
Oncology
Annals of
Oncology
Breast Cancer
Research
Sample
117 patients at IIIB
grade
23 IBC and 27
non-IBC
10 primary IBC
cases and five
non-IBC cases
88 patients who had
a residual tumor at
surgery
 55 IBC patients (25
Caucasian women
and 30 Afro-
American women)
who underwent
therapy with
curative intention
between 1995 and
2009
80 IBC patients who
took mammogram,
ultrasonic and MRI
before being
submitted to
neoadjuvant
chemotherapy
203 women with
diagnosed II/IV
grade IBC, with
acknowledged
(HER2) and its
respective status
women withIII/IV
grade IBC,
diagnosed between
2004 and 2007
IBC biopsies
conducted for
assessing cathepsin
B and caveolin-1
expression
Main findings
VEGF-A in stromal tumor is associated with lower
survival rate to breast cancer and recurrence in
IBC. When diagnosed at this grade, it might have
more effective prognostics leading to customized
therapy.
Positive correlation between nodal CTSB and
metastatic grade in IBC suggests that
thisproteolytic enzyme may lead to nodal
metastasis. When Caveolin-1is found to beover-
expressed in IBC, it is likely to activate CTSB at
cell surface where IBC spreads into the lymph
vessels and develops into metastasis in the lymph
nodes.
E-cadherin accumulation and subsequent over-
expression is responsible for both MARY-X
spheroids as well as the lymph-vascular emboli
and fosters. It also fosters resistance to apoptosis
and survival advantage. In the setting of the
lymph-vascular tumor embolus, E-cadherin does
not function as a suppressor gene, but rather as
an oncogene.
EZH2 is commonly identified in IBC and is
associated not only with unfavourable prognostics
variable, but also with a significant survival rate
decline. This might become an innovative IBC
treatment option.
Being Afro American or Caucasian did not appear
to impact adherence to treatment. However, with
limited follow-up, there was a trend towards a
decreased response to standard multi-therapy
treatment and worse outcomes in African American
patients than in Caucasian patients. More in-depth
follow-up and future studies should be conducted
to investigate the impact of race and new-targeted
agents in women with IBC.
Magnetic Resonance Imaging (MRI) is a major tool
in IBC diagnosis and staging, since it was successful
regarding primary breast disease in nearly 98%
of all patients – unlike mammography today. MR
higher and farther-reaching rate of diagnosis
makes it a powerful evaluative tool of therapy
response.
A highest median survival rate trend was observed
in women with Human Epidermal Growth Factor
Receptor 2 (HER2)-positive disease. IBC is
associated with high grade early brain metastasis,
which supports the notion that IBC might become
an ideal cohort to assess early detection or
preventive intervention aimed at reducing brain
metastasis incidence.
It appears that surgery of the primary IBC tumour
at IV grade is associated with improved
prognostics, indicating that aggressive treatment
both with systemic and local therapy may be
advisable for carefully selected groups of women
with IV grade IBC.
In vitro data show that cathepsin B cysteine
protease is engaged in type IV collagen
degradation and IBC cell invasion, probably by
translocating into caveolae so as to regulate cell
surface proteolysis. Therefore, clinical approaches
aiming to segment active cathepsin B may be
effective against IBC.
Author (year)
Arias-Pulido et al.3
(2012)
Nouh et al.4
(2011)
Ye et al.8
(2010)
Gong et al.9
(2011)
Andic et al.5
(2011)
Le-Petross et al.10
(2011)
Dawood et al.11
(2010)
Dawood et al.12
(2012)
Victor et al.13
(2011)
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Journal
British
Journal of
Cancer
The Brith Jornal
of Radiology
Molecular Cancer
Therapeutics
Breast Cancer
Res Treat
Breast Cancer
Res Treat
NIH Public
Access
Nutr Cancer
Cancer
Epidemiol
Biomarkers Prev
Breast Cancer
Res Treat.
Sample
Reducing GLI1
levels at protein
expression, cell
proliferation,
migration and
apoptosis
43 advanced or IBC
patients who had
undergone
neoadjuvant
chemotherapy
SUM149 cells
generated by
Asterand, Inc with
stable wtXIAP
expression and FG9
vector controls
generated by a
lentiviral expression
system
 274 contralateral
invasive breast
cancers were
identified in IBC
cases and 6,019 in
non-IBC cases
Apricoxib proved to
be an efficient PGE2
inhibitor in
twomammalian cell
culture lines -
SUM149 and
SUM190.27
IBC patient-derived
cells
Non-IBC 5.525 IBC
and 337.708
Paraffin blocks of
117 primary IBC
and 59 non-IBC
patients
Main findings
In the light of observed GLI1 role in proliferation,
survival and migration of a subset of IBC cells,
direct targeting of GLI1 transcription is suggested
as a novel and promising strategy for targeting
triple-negative/Basal B IBC modelled by SUM149
cells.
Estimates of residual tumour size based on MRI
just before surgery appear to correlate better with
pathological results than estimates or predictions
based on mammogram, CAT Scans or clinical
examination. It may overestimate or
underestimate residual disease in some patients.
Further studies are needed to assess the value of
MRI for evaluating the response and thus the
efficacy of chemotherapy earlier in a course of
neoadjuvant chemotherapy.
Show that Embelin primes IBC cells for TRAIL (TNF-
Related Apoptosis-Inducing Ligand) are mediated
by XIAP as a potent inhibitor of caspase activity
and unbalanced cell redox state regarding oxidative
stress. Therefore, ROS modulators may stand as
a promising approach to increase efficacy of TRAIL
and IBC based protocols.
Findings highlight importance of vigilant opposite
breast screening following IBC diagnosis. MRI
proved more accurate to detect breast parenchyma
injury. Low IBC survival rates and higher
contralateral breast cancer prognosis compared
with other types of breast cancer should guide
the assessment of risk management strategies for
post-IBC contralateral breast cancer.
Shows a highly efficient summary of promising
inhibitor of COX-2, apricoxib, a three-step method
applied to commercially available samples which
improvedã-ketoaldehyde intermediate 7 synthesis.
Multigramapricoxib quantities prepared for pre-
clinical trials proved to be inhibitors of COX-2 in
IBC cells.
Reishi is a potent anti-invasion agent to prevent
tumour spheroid formation and potential inhibitor
of IBC spread, whose action can be correlated with
reduced viability and inhibition of eIF4G, E-
cadherin, MMP-9 and p120-catenin, key proteins
responsible for tumour growth and IBC invasion.
Findings suggest that Reishi extract could be used
as a novel anticancer therapy for IBC patients.
Low socio-economic status women have less access
to health services and, therefore, to earlier breast
cancer detection.
Findings show lower survival rate in IBC patients
irrespective of hormone, chemo and radio therapy.
Antracycline-based chemo with or without one-year
administration of trastuzumab (pre-surgery
followed by adjuvant) showed that trastuzumab
resulted in significantly higher pathological
response and free-of-event survival rate in HER2-
positive patients.
Author (year)
Thomas et al.14
(2011)
SHIN, et al.15
(2011)
Allensworth et al.16
(2012)
Schairer et al.17
(2011)
Mandal et al.18
(2011)
Martínez
Montemayor
et al.19
(2011)
Schlichting
et al.20
(2012)
Chaher et al21
(2012)
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Author (year)
LI et al.22
(2011)
Ohshiro et al.23
(2012)
Bertucci et al.24
(2012)
Duke et al.25
(2010)
BOURGIER et
al.26(2010)
Sesgin et al.27
(2011)
Mailliez et al.28
(2010)
Schlichting et
al.29
(2012)
Journal
The Oncologist
PLoS ONE
PLoS ONE
Oncology
reports
Int. J. Radiation
Oncology Biol.
Phys
Med PrincPract
The Breast
journal
Breast Cancer
Res Treat
 Sample
316 IBC patients,
without distant
metastasis
SUM149A cell lines
from primary duct
carcinoma;
SUM190 from IBC
cells. MDA-MB-231
breast cancer cell
lines, MDAMB-468
and MCF-7 from
American
TypeCulture
Collection
Invasive
adenocarcinoma
tissue samples
were collected from
359 patients who
had been
submitted to
surgery biopsy or
initial surgery at
Institut Paoli-
Calmettes
18 people from the
same workplace –
three IBC and 15
non-IBC cases
124 patients with
non-metastatic IBC
45 patients withIBC
who had developed
distant metastasis
56 had a local-
regional IBC with
available
histopathologic
material
Main findings
A subtype of breast cancer, as established by ER, PR
and HER-2 substitute markers, is closely associated
with OS and LRR findings in IBC patients. TN subtype
consistently anticipated worst findings. Results can be
useful in establishing therapies for distant and
locoregional disease.
Provides evidence for p-RK1 / 2 supra-regulation
through immunocoloration of IBC samples and
suggests a non-genomic signaling role through
p-ERK 1/2 activation related to IBC hormone
dependence through a combination of estrogen
receptors.
These findings explain the failure of anti-estrogen
traditional therapies for ER-positive IBC that induce
non-genomic signalling. It also makes the case for
modified therapies using these estrogen receptors.
Monitoring this specific germinal variationcan become
a critical tool in IBC prognostics. Additionally, it is
suggested that allelic risk, when associated with low
sensitivity, can be correlated with high metastasis risk.
Combined workplace factors cannot account for the
three IBC cases. However, every woman was directly
exposed to tumour-associated agents and/or factors.
Long-lasting workplace conditions may have led to the
development of aggressive breast cancer.
Alternating chemo and radiotherapy yielded efficient
long-term local control without surgery. Long-term MFS
and OS rates were similar to those that resulted from
primary chemotherapy, total mastectomy and adjuvant
radiotherapy. IBC continues to have a dismal prognosis
and the current approach, safely combining radiation
therapy and systemic treatments, should be
reassessed when suitable targeted agents become
available.
Patients with p53 protein accumulation and visceral
organ involvement appear to have a significantly
shorter survival rate than those without such poor
prognosis. p53 status and presence or absence of
visceral metastasis are clinically useful tools for
prognosis and risk stratification in metastatic IBC.
However, larger prospective studies will be needed to
confirm these findings.
Study proposes a standardised sampling process with
a mastectomy at scale scheme with samplings of
residual tumour or cicatricial area collected every
centimetre and noted down on the scheme.
Additionally, another sampling to be systematically
collected in each quadrant, two samplings on the nipple
and one behind the nipple to evaluate tumour size.
Findings indicate IBC patients have lower survival rate
than non-IBC patients, most specifically for stage III
cancers. Residing in a lower SEP, non-metro county
may worsen BCS survival, though this was only
significant for non-IBC in multivariate proportional
hazards models. Afro-Americans appear to have lower
BCS survival regardless of inflammatory status, stage,
county level SEP, tumour, or treatment features.
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Determining features
Only three of the study samples5,20,25 investi-
gated determining features of the disease. For
Andicet al.5, no difference was assessed between
races at middle age, tumour size and receptor grade
and status. However, a trend emerged for pathologic
response, which was slightly higher in Caucasian
than in Afro-American women (P = 0,23) – a
generally higher survival rate (three years) in
Caucasian than in Afro-American women (P = 0,09)
and higher survival rate of distant metastasis
(P = 0,19). Racial features did not seem to affect
adherence to treatment.
Two studies 5, 20suggest that low socio-
economic status is associated with higherIBC
incidence, irrespective of a patient’s age/race/ethnic
group at diagnosis, and possibly associated with
lower educational level and poor access to health
services.
Duke et al.25investigated three specific cases
of IBC in the workplace within a time-span of 10
months, suggesting that oral contraceptives,
hormone replacement therapy, overweight and
exposure topesticides and herbicides might have
combined to result in such an unordinary number
ofIBC cases in the workplace. However, they did not
explain how combined workplace factors affected
the three people.
Diagnostics and treatment
Several studies investigated diagnosis and
treatment4,10,12-19,21,23,26,28, two of which10,15 show
that MRI (Magnetic Resonance Imaging) is
significantly more accuracy for diagnosing IBC. Le-
Petross9 argues that MRI has a 98% accuracy rate
in targeting IBC when compared with ultrasonic
imaging (94%) and a mammogram (65%). MRI
may also aid in assessing response to therapy. The
samples contradict current practices to track
breast cancer, of which the mammogram is the
most commonly used. Vigilant opposite breast
screening using MRI should be considered given
the low IBC survival rates and higher contralateral
breast cancer prognosis compared with other types
of breast cancer17.
With reference to treatment options, primary
grade IV IBC surgery is associated with better
prognostics, suggesting that systemic or local
therapy may be advisable for carefully selected
objects13. Nevertheless, Bourgieret al.26 monitored
124 women from the time their non-metastasis IBS
was diagnosed and suggest alternating chemo and
radiotherapy as an effective method for long-term
control without surgery. Chaher et al.21, however,
observed worse survival conditions in IBC patients,
irrespective of their being submitted to chemo, radio
or hormone therapy.
Some studies suggest novel treatments using
biological markers4,13. Victor et al.¹3 contend that
cathepsin B cysteine protease is engaged in type IV
collagen degradationand IBC cell invasion, probably
by translocating into caveolae so as to regulate cell
surface proteolysis. These in vitro findings are
supported by significant cathepsin B and caveolin-1
co-expression in IBC cell samples. Theirs is one of
the few studies which show that cathepsin B,
associated with caveolin-1, plays a role in
aggressive phenotype of IBC.
Two studies investigated plant active
principles. Martínez-Montemayor et al19 examined
the use of Reishi extract, a potent anti-invasion
agent to prevent tumour spheroid formation and
potential inhibitor of IBC spread and action can
be correlated with reduced viability and inhibition
of eIF4G, E-cadherin, MMP-9 and p120-catenin
– key proteins responsible for tumour growth and
IBC invasion. It is suggested that Reishi extract
could be used as a novel anticancer therapy for
IBC patients. Allensworth et al.16 described the
role played by apoptosis inhibitor related to X
when embelin, derived from a plant, is used in
combination withTRAIL – a proapoptotic receptor
agonist – to catalyse the death of this receptor.
Cell viability was lowered and TRAIL proved to
be a novice approach to higher IBC protocol.
GLI1 is a protein-coding gene that is able to
regulate cell proliferation, survival and
differentiation. Thus, Thomas et al.¹4 suggested
direct targeting of GLI1 transcription as a promising
strategic therapy for IBC patients.
Ohshiro et al.23 explored non-genomic
signalling of several estrogen and anti-estrogen
agents in IBC SUM149 and SUM190 cell lines and
identified a variant estrogen receptor (EEI), ERa36,
in SUM149 and SUM190 cells and a substantial
increase in cell migration and invasion of SUM149
cells when these ligands were used. Such findings
suggest a non-genomic signalling role through p-
ERK1/2 activation related to IBC hormone
dependence through a combination of estrogen
receptors, and explain the failure of anti-estrogen
traditional therapies for ER-positive IBC.
Mailliezet al.28compared the Complete
Pathologic Response(CPR) in 56 non-metastasis IBC
patients and assessed a possible correlation
betweenCPR and global survival. Initial biopsies and
mastectomy at scale scheme with samplings of
residual tumour or cicatricial area were revised by
the same pathologist. A 75% clinical response was
found, but no correlation between clinical and
pathological response. Neither response was
predictive of global relapse-free survival.
Prognostics
Prognostics-oriented studies explore mainly
biological factors that are good prognostics
markers3,8,9,11,22,24,27,29.
Seszinet al.27assessed prognostics markers
of IBC by examining resection samples of 45 IBC
patients who had developed distant metastasis.
Patients with p53 protein accumulation and visceral
organ involvement appear to have a significantly
shorter survival rate than those without such poor
prognosis.
EZH2, Enhancer of homolog zester2, is a
Polycomb protein that regulates cell cycle
progression and which is associated with many
malign tumours, including breast cancer. It is
associated not only with unfavourable prognostics
variable but also with a significant survival rate
decline9. Therefore, it might become an innovative
IBC treatment option.
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